Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells
- PMID: 1700746
- PMCID: PMC1535142
- DOI: 10.1111/j.1365-2249.1990.tb05463.x
Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells
Abstract
It has been reported that lymphocytes from peripheral blood (PBL) cultured with interleukin-2 (IL-2) produce predominantly CD16+ lymphokine-activated killer (LAK) cells. We developed a two-step method to generate LAK cells from human PBL in long-term cultures (10-12 days) with recombinant human IL-2 (rhIL-2) and characterized the evolving LAK cell population by testing its phenotype and cytotoxic activity as a function of time. The starting PBL displayed some natural killer (NK) cytotoxicity but no LAK activity. At day 6, the cells were a mixed population of about 80% CD3+ and 6% CD16+ cells. Little proliferation was evident but strong LAK activity was detected. After 10-12 days, major cell expansion had occurred and they were essentially a pure (greater than 90%) CD3+ CD16- CD56- cell population large granular lymphocyte (LGL) by morphology that displayed strong non-MHC-restricted killing activity (greater than 200 lytic units). Over the same period of time, the CD16+ cells had almost completely regressed in these cultures. This preferential induction of CD+ LAK cells was not an effect of IL-2 concentration as 10 U/ml was as effective as 500 U/ml. Further characterization revealed a major population of CD4+ (60%) and CD8+ (30%) with a smaller fraction (less than 9%) of gamma delta + cells. These results indicate that a virtually pure CD3+ LAK cells population was produced with long-term cultures of lymphocytes from peripheral blood in rhIL-2, in which active proliferation of the CD3+ but not CD16+ cells occurred.
Similar articles
-
Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.Cancer Res. 1989 Feb 15;49(4):963-8. Cancer Res. 1989. PMID: 2521457
-
NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.Cell Immunol. 1990 Mar;126(1):211-26. doi: 10.1016/0008-8749(90)90313-g. Cell Immunol. 1990. PMID: 1689220
-
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.Cancer Res. 1989 Jul 1;49(13):3680-8. Cancer Res. 1989. PMID: 2471587
-
Human liver-associated lymphocytes: an overview.J Gastroenterol Hepatol. 1995;10 Suppl 1:S43-6. doi: 10.1111/j.1440-1746.1995.tb01796.x. J Gastroenterol Hepatol. 1995. PMID: 8589341 Review.
-
Human cytotoxic effector cells: definition and analysis of activity.Allergol Immunopathol (Madr). 1991 Jul-Aug;19(4):145-56. Allergol Immunopathol (Madr). 1991. PMID: 1726345 Review.
Cited by
-
Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.Cancer Immunol Immunother. 1994 Nov;39(5):305-12. doi: 10.1007/BF01519983. Cancer Immunol Immunother. 1994. PMID: 7987862 Free PMC article.
-
Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans.Infect Immun. 1991 Oct;59(10):3393-7. doi: 10.1128/iai.59.10.3393-3397.1991. Infect Immun. 1991. PMID: 1894353 Free PMC article.
-
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.J Cancer Res Clin Oncol. 1993;119(12):745-55. doi: 10.1007/BF01195347. J Cancer Res Clin Oncol. 1993. PMID: 8408187 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials